# US 2012/0253013 A1 · Early Growth Transcription Factors and Their Therapeutic Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253013 A1
- Document ID: US20120253013A1
- Status: Published application
- Kind: A1
- Application number: 13/391,681
- Filed: 2010-08-25
- Published: 2012-10-04
- Earliest claimed: 2009-08-25
- Inventors: Dan Liu; Ian Charles Zachary
- Web page: https://patentgrep.com/patent/US20120253013A1

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/02: for peripheral neuropathies
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention comprises a nucleotide which encodes a protein, wherein the protein includes an amino acid sequence having at least 95% homology to SEQ ID NO: 1 (Egr3 DNA binding domain), for use in therapy.

## Claims

### Claim 1

A nucleotide which encodes a protein, wherein the protein includes an amino acid sequence having at least 95% homology to SEQ ID NO: 1 (Egr3 DNA binding domain), for use in therapy.

### Claim 2 (depends on 1)

A nucleotide according to claim 1, wherein the protein includes an amino acid sequence having at least 95% homology to SEQ ID NO: 5 (ΔEgr3).

### Claim 3 (depends on 1, 2)

A nucleotide according to claim 1 or claim 2, wherein the protein includes an amino acid sequence having at least 95% homology to SEQ ID NO: 4 (Egr3).

### Claim 4

A nucleotide according to any preceding claim, wherein the homology is 100%.

### Claim 5

A vector comprising a nucleotide according to any preceding claim, for use in therapy.

### Claim 6 (depends on 5)

A vector according to claim 5, which is an adenovirus.

### Claim 7 (depends on 1, 2, 3, 4)

A protein as defined in any of claims 1 to 4, for use in therapy.

### Claim 8

A nucleotide, protein or vector according to any preceding claim, wherein the therapy is of a condition where neuronal regeneration is beneficial.

### Claim 9 (depends on 8)

A nucleotide, protein or vector according to claim 8, wherein the condition is peripheral neuropathy, nerve injury, spinal injury or stroke.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7)

A nucleotide, protein or vector according to any of claims 1 to 7, wherein the therapy is of a neovascular disease.

### Claim 11 (depends on 10)

A nucleotide, protein or vector according to claim 10, wherein the neovascular disease is cancer, diabetic retinopathy, atherosclerosis or rheumatoid arthritis.
